Zdrowie i gospodarka · 18/10/2022
FDA Announces Draft Guidance for Industry on Tissue Agnostic Drug Development in Oncology
The FDA has released a draft guidance outlining the development of tissue agnostic drugs, which target specific molecular alterations across multiple cancer types, with the goal of accelerating the creation of new therapies for rare cancer patients.